News coverage about Fulgent Genetic (NASDAQ:FLGT) has trended somewhat positive this week, Accern Sentiment reports. Accern ranks the sentiment of press coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Fulgent Genetic earned a news sentiment score of 0.21 on Accern’s scale. Accern also assigned news stories about the company an impact score of 46.9587339191442 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
Fulgent Genetic (FLGT) traded down $0.08 during mid-day trading on Tuesday, hitting $3.67. The stock had a trading volume of 23,000 shares, compared to its average volume of 46,263. The firm has a market capitalization of $66.84, a PE ratio of 187.50 and a beta of 1.27. Fulgent Genetic has a 52 week low of $2.72 and a 52 week high of $13.90.
FLGT has been the subject of several recent analyst reports. Credit Suisse Group lowered their price target on Fulgent Genetic from $11.00 to $10.00 and set an “outperform” rating for the company in a report on Tuesday, August 8th. Piper Jaffray Companies restated an “overweight” rating and issued a $7.00 price target (down from $10.00) on shares of Fulgent Genetic in a report on Wednesday, August 9th. Zacks Investment Research downgraded Fulgent Genetic from a “hold” rating to a “sell” rating in a report on Monday, August 14th. ValuEngine upgraded Fulgent Genetic from a “sell” rating to a “hold” rating in a report on Monday, October 2nd. Finally, Raymond James Financial downgraded Fulgent Genetic from an “outperform” rating to a “mkt perform” rating in a report on Tuesday, November 7th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and two have issued a buy rating to the company’s stock. The stock has an average rating of “Hold” and an average price target of $7.25.
In other news, insider Ming Hsieh acquired 10,504 shares of Fulgent Genetic stock in a transaction dated Tuesday, November 14th. The stock was bought at an average cost of $3.30 per share, with a total value of $34,663.20. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders have bought 33,488 shares of company stock valued at $112,769 over the last ninety days. 58.80% of the stock is owned by insiders.
About Fulgent Genetic
Fulgent Genetics, Inc is a technology company. The Company offers genetic testing to provide physicians with clinically actionable diagnostic information to improve quality of patient care. The Company has developed a technology platform that integrates data comparison and suppression algorithms, adaptive learning software, advanced genetic diagnostics tools and integrated laboratory processes.
Receive News & Ratings for Fulgent Genetic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fulgent Genetic and related companies with MarketBeat.com's FREE daily email newsletter.